U.S. Department of Ommerce Perent and Trademark Office	Docket No.: UCSD1590	Serial No.: 09/454,223
FEB 2 8 2005 E	Applicant(s): Richard S. Korn	ıbluth
INFORMATION DISCLOSURE TATEMENT	Filing Date:	Group Art Unit:
BY APPLICANT TRANSMAN	December 9, 1999	1647

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
-\$\$	AA	6,190,886	02/20/01	Hoppe et al.	435	69.7	
	AB	5,716,805	02/10/98	Srinivasan et al.	435	69.1	
	AC	5,962,406	10/05/99	Armitage et al.	514	8	
	AD	6,018,026	01/25/00	Sledziewski et al.	530	350	
	AE	2003/0053984	03/20/03	Tschopp et al.	424	85.1	
	AF	2004/0047873	03/11/04	Al-Shamkhani et al.	424	185.1	
V	AG	2004/0248801	12/09/04	Kiessling et al.	514	12	

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
3	AH	WO 93/08207	29.04.1993	PCT		-	
ľ	ΑI	WO 03/068799	21.08.2003	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

-88	AJ	Morris et al., "Incorporation of an Isoleucine Zipper Motif Enhances the Biological Activity of Soluble CD40L (CD154)", The Journal of Biological Chemistry, Vol. 274, No. 1, pp. 418-423, (1999).
-----	----	--

EXAMINER	Ø 1 2	DATE CONSIDERED	6/9/0
GT\6394212.1 101668-179	Ofel		6 \ 00-2

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No.: UCSD1590	Serial No.: 09/454,223		
	Applicant(s): Richard S. Kornbluth			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: December 9, 1999	Group Art Unit: 1647		

-58	AK	Holler et al., "Two Adjacent Trimeric Fas Ligands Are Required for Fas Signaling and Formation of a Death-Inducing Signaling Complex", Molecular and Cellular Biology, Vol. 23, No. 4 (2003).
	AL	Haswell et al., "Analysis of the Oligomeric Requirement for Signaling by CD40 using Soluble Multimeric Forms of Its Ligand, CD154", Eur. J. Immunol., Vol. 31:3094-3100 (2001).
	+	

EXAMINER	921 8	DATE CONSIDERED
GT\6394212.1 101668-179		6/rlos

FÜRM PTG-1449 U.S. Bepartment of Commerce Patent and Trademark Office	Docket No.: UCSD1590	Serial No.: 09/454,22	23 OIPE
	Applicant(s): Richard S. Ke	ornbluth	MAY 1 2m, S
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: December 9, 1999	Group Art Un 1647	

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
_						

FOREIGN PATENT DOCUMENTS

EXAM INITIA			DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
-39	,	AA	WO 94/10308	05/11/1994	PCT			
		AB	WO 99/04000	01/28/1999	PCT			
	,	AC	WO 01/16180	03/08/2001	PCT			
V		ΑD	WO 01/49866	07/12/2001	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

35	AE	Haswell et al., "Analysis of the oligomeric requirement for signaling by CD40 using multimeric forms of its ligand, CD154", Eur. J. Immunol, Vol. 31, pp. 3094-3100, (2001).
	AF	Hoppe et al., "A parallel three stranded α-helical bundle at the nucleation site of collagen triple-helix formation", FEBS Letters, Vol. 344, pp. 191-195, (1994).
	AG	Kishore et al., "Modular organization of proteins containing C1q-like globular domain", Immunopharmacology, Vol. 42, pp. 15-21, (1999).
1	AH	Kombluth et al., "CD40L (CD154) fusion protein with pulmonary surfactant protein D as a prototype for soluble multimeric TNF superfamily ligand molecules", FASEB Journal, Vol. 14, No. 6, A1162, (2000).

F		
EXAMINER	911 0	DATE CONSIDERED ,
li	Jely	[algin\
	~	0 1(0)

EORM PTO-1449 U.S. Bepartment of Commerce Patent and Trademark Office	Docket No.: UCSD1590	Serial No.: 09/454,223	OIPE
	Applicant(s): Richard S. Kornbluth		MAY 1 4 2000
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: December 9, 1999	Group Art Unit: 1647	E AND WELL

	_	
-\$\$	Al	Pound et al., "Minimal cross-linking and epitope requirements for CD40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells", <i>International Immunology</i> , Vol. 11, No. 1, pp.11-20, (1999).
	AJ	Sano et al., "Analysis of Chimeric Proteins Identifies the Regions in the Carbohydrate Recognition Domains of Rat Lung Collectins That Are Essential for Interactions with Phospholipids, Glycolipids, and Alveolar Type II Cells", J. Biol. Chem, Vol. 273, No. 8, pp. 4783-4789, (1998).
V	AK	Schneider et al, "Conversion of Membrane-bound Fas (CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver Toxicity", J. Exp. Med., Vol. 187, No. 8, pp. 1205-1213, (1998).

EXAMINER	DATE	CONSIDERED 9	νΥ	